| Subclinical Atherosclerosis Noted in Diffuse Scleroderma |
 |
 |
 |
| Saturday, 15 September 2012 13:59 |
|
Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis, according to a study published online Aug. 16 in Arthritis Care & Research.
To identify signs of early cardiovascular involvement in SSc, Maurizio Turiel, M.D., of the University of Milan, and colleagues conducted a pilot study involving 20 patients with diffuse SSc but no signs of cardiovascular disease, and 20 age- and gender-matched control patients. The researchers found that arterial wall measurements were significantly different in SSc versus control patients. Compared with controls, in SSc patients, right and left carotid intima-media thickness, pulse wave velocity, and stiffness index β were also significantly elevated. Coronary flow reserve was significantly lower and plasma levels of asymmetric dimethylarginine levels were significantly higher in those with SSc compared with healthy controls. "In conclusion, patients with diffuse SSc seem to have subclinical cardiovascular involvement, as demonstrated by various methods," the authors write. "Further studies are required to define more precise algorithms for assessing and managing cardiovascular disease in SSc patients." Source: Healthday (2012), "Subclinical Atherosclerosis Noted in Diffuse Scleroderma"; Original article can be viewed here. |
More articles :
» Erectile Dysfunction is Frequent in Systemic Sclerosis and Associated with Severe Disease: A Study of the EULAR Scleroderma Trial and Research Group
Chingching Foocharoen, Alan Tyndall, Eric Hachulla, Edoardo Rosato, Yannick Allanore, Dominique Farge-Bancel, Paola Caramaschi, Paolo Airó, Starovojtova M Nikolaevna, José A Pereira da Silva, Bojana Stamenkovic, Gabriela Riemekasten, Simona...
» Biomarkers Predict Lung Decline in Systemic Sclerosis
Predicting risk of pulmonary fibrosis and pulmonary hypertension is an urgent priority in systemic sclerosis. Lung function often declines rapidly in the first years after diagnosis, and interstitial lung disease (ILD), although highly variable in...
» New Genetic Path Targeted For Scleroderma Therapy
A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy. The finding, discovered by a cross-disciplinary team led by John Varga, MD, John and...
» The Dendritic Cell and The Link between Atherosclerosis and Autoimmunity
Individuals who suffer from autoimmune diseases also display a tendency to develop – the condition popularly known as hardening of the arteries. Clinical researchers at LMU, in collaboration with colleagues in Würzburg, have now discovered a...
» Report on the 2010 Systemic Sclerosis World Congress
Robert J. Riggs, CEO of the recently reported on his experience at the recently concluded , held in Florence, Italy. Here's a brief excerpt. In February, I attended the 1st World Congress on Systemic Sclerosis in Florence, Italy. The three-day...
» New, Non-invasive Test May Help Diagnose Pulmonary Hypertension in Scleroderma
In patients with Systemic Sclerosis (SSc) – or – a condition called pulmonary hypertension (PH) is a leading cause of death. Having PH means the blood pressure between the heart and lungs is elevated.The Need for New Tests for PH in SScThe...